CombiGene, together with its Danish partner Zyneyro, has received welcome financial support of 8,6 million SEK from Eurostars for the continued development of the peptide COZY1, a drug candidate for the treatment of severe chronic pain conditions. BioStock reached out to CombiGene’s CEO Peter Ekolind for a comment.
Read the article from BioStock here: CombiGene comments on Eurostars funding – BioStock